Epidermal Differentiation Disorders
Why ichthyosis and related skin conditions have been reclassified — and what this means for your diagnosis.
What Has Changed
In 2024–2025, dermatologists and clinical geneticists across Europe and the UK began formally adopting the term "Epidermal Differentiation Disorders" (EDD) as an umbrella classification covering ichthyoses, palmoplantar keratodermas (PPK), and related inherited skin conditions.
This is part of a broader shift in how inherited skin diseases are categorised — moving away from what the skin looks like towards which gene or biological pathway is affected.
Old approach: Clinical phenotype classification
New approach: Molecular pathology classification
What's Included Under "Epidermal Differentiation Disorders"
Epidermal Differentiation Disorders (EDD)
All of the following conditions share the same disease group under the new classification:
Key Biological Pathways Affected
The EDD framework groups conditions by which molecular pathway is disrupted. Understanding this is increasingly important for targeted therapy development:
Structural Protein Defects
The most common group. Affects the process of normal skin cell maturation and cornification (formation of the skin's protective outer layer).
Epidermal Lipid Barrier Defects
Affects the lipid envelope surrounding skin cells. Critical for barrier function. Most ARCI non-TGM1 subtypes fall here.
Lamellar Body Secretion Defects
Affects transport of lipids into the extracellular space. The most severe ichthyosis — Harlequin — is in this group.
Protease / Anti-Protease Imbalance
Affects the regulation of serine proteases in skin. Results in both structural and immune abnormalities.
Nucleotide Excision Repair Defects
Affects repair of UV-damaged DNA. Results in photosensitivity, hair shaft abnormalities, and often neurological involvement.
Steroid Sulfatase Deficiency
Cholesterol sulfate accumulates in the stratum corneum, disrupting shedding. One of the most common single-gene inherited skin disorders.
What This Means for You as a Patient
If you were diagnosed with Lamellar Ichthyosis, Netherton Syndrome, Ichthyosis Vulgaris, or any other specific type — that diagnosis remains valid. The EDD umbrella is a classification system, not a new condition. Your specific type name and gene remain the same.
The reclassification is academic and research-focused. Your emollients, medications, and management plan are unchanged. Treatment decisions continue to be based on your specific gene mutation and clinical presentation.
The broader EDD umbrella means that rare disease funding bodies and clinical trial eligibility criteria can encompass more patients. Trials targeting "EDD" may include PPK and ichthyosis patients together, increasing enrolment opportunities.
Under the EDD framework, knowing your gene mutation is central to your classification. If you haven't had genetic testing, the new classification gives additional reason to request it — your gene determines which pathway is affected and which emerging treatments are most relevant to you.
Adoption Timeline
European Consensus Published
European dermatology and genetics societies published a consensus document on the reclassification of inherited epidermal disorders under the EDD framework. Proposed standardised pathway-based nomenclature.
UK Dermatology Community Adoption Begins
Major UK dermatology centres and the British Association of Dermatologists begin using EDD terminology in clinical documentation, rare disease registries, and funding applications.
Transitional Period — Both Terms in Use
Many clinicians continue to use condition-specific names (Lamellar Ichthyosis, Netherton Syndrome) alongside EDD classification. Both are correct. This transitional period is expected to continue for several years.
Full Integration Expected
EDD expected to become standard in NHS rare disease pathways, NICE guidance, and clinical trial design. Specific type names will remain in use alongside the EDD umbrella classification.